Login
Home
About Us
Contact Us
Site Map
Search for
Home
>
Knowledge Centre
>
Online Learning & Teaching
>
ESC Slide Resource
>
ESC Congress 2003 Vienna
Online Learning & Teaching
Webcasts
ESC Slide Resource
World Congress of Cardiology - ESC Congress 2006
ESC Congress 2005 Stockholm
ESC Congress 2004 Munich
ESC Congress 2003 Vienna
Management of CVD Risk in the Perimenopausal Woman 2006
EACPR Leuven Spring Meeting 2005
Heart Failure 2005
ESC Policy Conference on CVD in Women
Education in Heart
Educational Programme Resources
Scientific and Knowledge Search
Clinical Case Portal
Echocardiography
Heart Failure Scientific Reports
CME Calendar
Management of the high-risk patient with angiotensin-converting enzyme inhibitors
Presentation title:
Management of the high-risk patient with angiotensin-converting enzyme inhibitors
Author(s):
S. Yusuf (Hamilton, CA)
Date:
01 September 2003
[Download complete file]
Click a thumbnail below to view an individual slide:
MULTIPLE MECHANISMS OF ACE-I
Mortality in SOLVD Trials
ACE-I: OVERVIEW: MORTALITY
HF Development in Prevention Trial
Ischemic Events in SOLVD Trials
SUMMARY OF KEY RESULTS FROM OVERVIEW OF LONG TERM TRIALS OF ACE-I
Cumulative 12-Year Survival in Prevention Trial
Cumulative 12-Year Survival in Treatment Trial
12-Year Cardiac Mortality in SOLVD Trials
Increase in Life Expectancy by Enalapril in Combined Trials
Primary Adjudicated Events - Ramipril vs Placebo
Outcome by Baseline Medication: Aspirin/BB/Lipid
All CHF - Ramipril vs Placebo
Development of DM: Ramipril vs Placebo
Events Prevented per 1,000 Patients Treated
Primary Outcome: All + Extension
Impact of ACE-Inhibitors on Mortality or Morbidity
Comparison of Cost Effectiveness of Ramipril Treatment with Other CV & Non-CV Interventions
ACE-inhibitors in the Prevention of Cardiovascular/Renal Disease
Conclusions: ACE-I in CVD
There are no polls available right now.
Site Map
|
Contact Us
|
Terms & Conditions
|
Privacy
Copyright © European Society of Cardiology 1997 - 2005 - All rights reserved